View:
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUERS PURSUANT TO RULE
13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
OF 1934
Dated: September 23, 2002
Commission file number 0-21392
AMARIN CORPORATION PLC
(Exact name of Registrant as Specified in its Charter)
ENGLAND
(Jurisdiction of Incorporation or
organization of Issuer)
7 Curzon Street
London W1J 5HG, England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or
Form 40-F.
[X] Form 20-F [ ] Form 40-F
Indicate by check mark whether the registrant by
furnishing the information contained in this Form is
also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
[ ] Yes [X] No
Attachment:
Material Events
(a) Amarin Corporation plc announces appointment of Vice President, Regulatory
Affairs.
This report on Form 6-K is hereby incorporated
by reference in the registration statement on Form F-3
(Registration Statement No. 333-12642) of Amarin
Corporation plc and in the prospectus contained therein,
and in the Registration Statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc
and in the prospectus contained therein, and this report
on Form 6-K shall be deemed a part of each such
registration statement from the date on which this
report is filed, to the extent not superseded by
documents or reports subsequently filed.
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMARIN CORPORATION PLC
By:/s/Richard A B Stewart
Richard A B Stewart
Chief Executive Officer
Date: September 23, 2002
Index to
Exhibits
Exhibit Item Sequentially Numbered Page
(a) Material Event description- 4
Amarin Corporation announces appointment
of Vice President, Regulatory Affairs
Exhibit
(a)
Contacts:
Rick Stewart Mike Coffee
Chief Executive Officer President and Chief Operating Officer
Amarin Corporation plc Amarin Corporation plc
Phone: +44 (0) 207 907 2440 Phone: +415 389 4755
Email: rick.stewart@amarincorp.com Email: mike.coffee@amarinpharma.com
AMARIN CORPORATION ANNOUNCES APPOINTMENT OF VICE PRESIDENT,
REGULATORY AFFAIRS
Amarin Also Announces Consolidation of U.S. Operations in San
Francisco, Planned Closure of New Jersey Office
London, United Kingdom, September 23, 2002 -- Amarin Corporation
plc (NASDAQ: AMRN) today announced the appointment of Margie
Nemcik-Cruz as Vice President, Regulatory Affairs of Amarin
Pharmaceuticals, Inc., its U.S. drug development and marketing
subsidiary.
"We are very pleased to have Margie join the Amarin team," said
Rick Stewart, chief executive officer. "Based on her outstanding
track record of progressing innovative new pharmaceutical products
through the regulatory approval process, including direct
interaction with the U.S. Food and Drug Administration for both
New Drug Application approvals and post-approval activities,
Margie's experience will be invaluable to Amarin as we continue to
advance our development pipeline."
Mike Coffee, president and chief operating officer, added,
"Attracting Margie completes the Amarin Pharmaceuticals management
team, where we now have experienced senior management in place for
all of the functions associated with our U.S. pharmaceutical
development and marketing activities."
Prior to joining Amarin, Ms. Nemcik-Cruz most recently operated an
independent regulatory consultancy. She previously spent several
years with increasing responsibilities at prominent pharmaceutical
companies, including Wyeth Laboratories, Sugen (since acquired by
Pharmacia) and most recently was Director, Regulatory Affairs at
Salix Pharmaceuticals. Ms. Nemcik-Cruz received a BSc in
Biochemistry from McGill University and an MA in Bio-organic
Chemistry from Brandeis University.
Amarin also announced the closure, by year-end, of its Warren, New
Jersey direct marketing facility. Direct marketing functions will
be consolidated in its existing offices near San Francisco.
Commenting on the consolidation, Mr. Stewart said, "The Amarin
Pharmaceuticals operation in San Francisco performs all primary
activities for our principal marketed product, Permax (r)
(pergolide mesylate tablets), plus our development stage products,
including Zelapar ( tm ) (selegiline orally dissolving tablets)
and LAX-101 for Huntington's disease. The completion of our U.S.
management team facilitates the consolidation of our remaining
activities resulting in greater efficiency, improved
communications and potential for cost savings."
Amarin Corporation plc is a specialty pharmaceutical company focused
on neurology and pain management. The Company plans to become a
leader in these therapeutic categories by providing innovative
products and solutions that address significant unmet medical needs.
Statements in this press release that are not historical facts are
forward-looking statements that involve risks and uncertainties
which may cause the Company's actual results in future periods to
be materially different from any performance suggested herein.
Such risks and uncertainties include, without limitation, risks
associated with the inherent uncertainty of pharmaceutical
research, product development and commercialisation, FDA approval,
the impact of competitive products and patents, as well as other
risks and uncertainties detailed from time to time in periodic
reports. For more information, please refer to Amarin
Corporation's Annual Report for 2001 on Form 20-F and its Form 6-Ks
as filed with the U.S. Securities and Exchange Commission. The
company assumes no obligation to update information on its
expectations.